<DOC>
<DOCNO>EP-1100482</DOCNO> 
<TEXT>
<INVENTION-TITLE>
USE OF CALIX(N)ARENES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING FIBROTIC DISEASES
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3118	A61K3118	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention concerns the use of calix(n)arenes for making a medicine for treating fibrotic diseases. The diseases treated can in particular be acute fibrosis caused by trauma and chronic fibrosis of major organs. Said calix(n)arenes are advantageously designed for topical treatment of the skin.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
CENTRE NAT RECH SCIENT
</APPLICANT-NAME>
<APPLICANT-NAME>
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
AUBERT-FOUCHER ELISABETH
</INVENTOR-NAME>
<INVENTOR-NAME>
COLEMAN ANTONY
</INVENTOR-NAME>
<INVENTOR-NAME>
HULMES DAVID
</INVENTOR-NAME>
<INVENTOR-NAME>
AUBERT-FOUCHER, ELISABETH
</INVENTOR-NAME>
<INVENTOR-NAME>
COLEMAN, ANTONY
</INVENTOR-NAME>
<INVENTOR-NAME>
HULMES, DAVID
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of calix(n)arenes in the manufacture of a medicament for treating
fibrotic diseases.
Use according to claim 1 
characterized in that
 the calix(n)arenes inhibit
lysyl oxidase activity.
Use according to one of claims 1 and 2 
characterized in that
 the
calix(n)arenes have the formula I as follows:



wherein

R
1
 represents an alkyl, alkylamide, acyl, aryl, carboxyl, sulfonyl or
phosphonyl group, optionally substituted
R
2
 represents a hydrogen atom, or an alkyl, acyl or amide group,
optionally substituted,
n is an integer between 4 and 8,
and their pharmaceutically acceptable salts and esters.
Use according to claim 3, 
characterized in that
 R
1
 represents a SO
3
H
group.
Use according to one of claims 3 and 4, 
characterized in that
 n is
equal to 6. 
Use according to one of claims 3 to 5, 
characterized in that
 R
2
 is a
hydrogen atom.
Use according to one of claims 3 to 6, 
characterized in that
 the
calix(n)arene is such that n is equal to 6, R
1
 is a SO
3
H group and R
2
 is a
hydrogen atom.
Use according to one of claims 3 to 7, 
characterized in that
 the
pharmaceutically acceptable salt is a lithium, sodium, potassium, rubidium or

cesium salt.
Method in vitro for inhibiting lysyl oxidase activity comprising bringing
the lysyl oxidase into contact with a calix(n)arene.
Method according to claim 9 
characterized in that
 the calix(n)arene
has the formula I according to claim 3.
Use in vitro of calix(n)arenes to inhibit lysyl oxidase activity.
</CLAIMS>
</TEXT>
</DOC>
